首页> 美国卫生研究院文献>other >Dosing Regimen of Enrofloxacin Impacts Intestinal Pharmacokinetics and the Fecal Microbiota in Steers
【2h】

Dosing Regimen of Enrofloxacin Impacts Intestinal Pharmacokinetics and the Fecal Microbiota in Steers

机译:恩诺沙星的给药方案会影响肠道中的药代动力学和粪便微生物群

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: The intestinal concentrations of antimicrobial drugs that select for resistance in fecal bacteria of cattle are poorly understood. Our objective was to associate active drug concentrations in the intestine of steers with changes in the resistance profile and composition of the fecal microbiome.>Methods: Steers were administered either a single dose (12.5 mg/kg) or 3 multiple doses (5 mg/kg) of enrofloxacin subcutaneously every 24 h. Enrofloxacin and ciprofloxacin concentrations in intestinal fluid were measured over 96 h, and the abundance and MIC of E. coli in culture and the composition of the fecal microbiota by 16S rRNA gene sequencing were assessed over 192 h after initial treatment.>Results: Active drug concentrations in the ileum and colon exceeded plasma and interstitial fluid concentrations, but were largely eliminated by 48 h after the last dose. The concentration of E. coli in the feces significantly decreased during peak drug concentrations, but returned to baseline by 96 h in both groups. The median MIC of E. coli isolates increased for 24 h in the single dose group, and for 48 h in the multiple dose group. The median MIC was higher in the multiple dose group when compared to the single dose group starting 12 h after the initial dose. The diversity of the fecal microbiota did not change in either treatment group, and taxa-specific changes were primarily seen in phyla commonly associated with the rumen.>Conclusions: Both dosing regimens of enrofloxacin achieve high concentrations in the intestinal lumen, and the rapid elimination mitigates long-term impacts on fecal E. coli resistance and the microbiota.
机译:>目的:人们对在牛粪便细菌中选择抗药性的抗菌药物的肠道浓度了解得很少。我们的目标是将公牛肠道中的活性药物浓度与粪便微生物组的耐药性和组成变化联系起来。>方法:公牛以单剂量(12.5 mg / kg)或3每24小时皮下注射多剂量(5 mg / kg)的恩诺沙星。在初始治疗后的192小时内,测量肠道液中恩诺沙星和环丙沙星的浓度,并通过16S rRNA基因测序评估培养物中大肠杆菌的丰度和MIC以及粪便微生物群的组成。>结果: 回肠和结肠中的活性药物浓度超过了血浆和组织液的浓度,但在最后一次给药后48小时已基本消除。在药物峰值浓度期间,粪便中的大肠杆菌浓度显着降低,但两组均在96小时后恢复到基线。在单剂量组中,大肠杆菌分离物的中位MIC增加了24小时,在多剂量组中增加了48小时。与初始剂量后12小时开始的单剂量组相比,多剂量组的中位MIC更高。在两个治疗组中,粪便微生物群的多样性均未改变,且分类群特异性的改变主要见于通常与瘤胃有关的门。>结论:恩诺沙星的两种给药方案均在肠道内达到高浓度腔,快速消除减轻了对粪便大肠杆菌抵抗力和微生物群的长期影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号